Journal Browser

Journal Browser

Special Issue "Disease Remediation Using Phytochemicals and Nano-Materials"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Prof. Dr. Vivek K. Bajpai
E-Mail Website
Guest Editor
Department of Energy & Materials Engineering, Dongguk University-Seoul, Seoul, Korea
Interests: metabolic disorders; nanotechnology; cancer biology; food and industrial microbiology; disease control; molecular biology; toxicology
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Cutting-edge biomedicines have a particular emphasis on the development of novel phytochemicals and nanomaterials for disease diagnosis, treatment, and monitoring treatment response of diseases. Among various materials, phytochemicals and nanomaterials have attracted considerable attention in recent years. Phytochemicals comprise a large portion of current-day pharmaceutical agents. These structurally unique agents function by novel mechanisms of action against serious metabolic diseases. The growing interest in developing multitargeted therapies may provide another golden opportunity to develop phytochemicals as new therapeutic agents. In addition, the developed nanomaterials can be easily used for the detection and visualization of important biomarkers inside the body and thus benefit the diagnosis of various diseases. The nanomaterials designed at the nanoscale level have also contributed significantly to disease treatment, such as cancer therapy, by delivering drugs, genes, small molecules, and proteins to specific diseased lesions.

In this context, this Special Issue aims to provide a forum for communication among scientists in the fields of phytochemical and nanomaterial sciences, and nanophytotheranostics. The research topic is designed to bring up recent findings of newly identified antidots as natural products and nanomaterials on this platform to combat various diseases. We would like to invite review and original articles that focus on understanding in vitro and in vivo efficacy and pharmacological and toxicological properties of natural products and nanomaterials especially as antidisease agents. Articles pertaining to any disease and therapeutic models are also welcome to this Special Issue.

Prof. Dr. Vivek K. Bajpai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Anticancer compounds
  • Molecular targets
  • Therapeutic models
  • In vivo and in vitro models
  • Nanomaterials
  • Nanoformulations

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Inhibition of Lipid Accumulation and Cyclooxygenase-2 Expression in Differentiating 3T3-L1 Preadipocytes by Pazopanib, a Multikinase Inhibitor
Int. J. Mol. Sci. 2021, 22(9), 4884; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094884 - 05 May 2021
Viewed by 178
Pazopanib is a multikinase inhibitor with anti-tumor activity. As of now, the anti-obesity effect and mode of action of pazopanib are unknown. In this study, we investigated the effects of pazopanib on lipid accumulation, lipolysis, and expression of inflammatory cyclooxygenase (COX)-2 in differentiating [...] Read more.
Pazopanib is a multikinase inhibitor with anti-tumor activity. As of now, the anti-obesity effect and mode of action of pazopanib are unknown. In this study, we investigated the effects of pazopanib on lipid accumulation, lipolysis, and expression of inflammatory cyclooxygenase (COX)-2 in differentiating and differentiated 3T3-L1 cells, a murine preadipocyte. Of note, pazopanib at 10 µM markedly decreased lipid accumulation and triglyceride (TG) content during 3T3-L1 preadipocyte differentiation with no cytotoxicity. Furthermore, pazopanib inhibited not only expression of CCAAT/enhancer-binding protein-α (C/EBP-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), and perilipin A but also phosphorylation of signal transducer and activator of transcription (STAT)-3 during 3T3-L1 preadipocyte differentiation. In addition, pazopanib treatment increased phosphorylation of cAMP-activated protein kinase (AMPK) and its downstream effector ACC during 3T3-L1 preadipocyte differentiation. However, in differentiated 3T3-L1 adipocytes, pazopanib treatment did not stimulate glycerol release and hormone-sensitive lipase (HSL) phosphorylation, hallmarks of lipolysis. Moreover, pazopanib could inhibit tumor necrosis factor (TNF)-α-induced expression of COX-2 in both 3T3-L1 preadipocytes and differentiated cells. In summary, this is the first report that pazopanib has strong anti-adipogenic and anti-inflammatory effects in 3T3-L1 cells, which are mediated through regulation of the expression and phosphorylation of C/EBP-α, PPAR-γ, STAT-3, ACC, perilipin A, AMPK, and COX-2. Full article
(This article belongs to the Special Issue Disease Remediation Using Phytochemicals and Nano-Materials)
Show Figures

Figure 1

Back to TopTop